Aflibercept Drug - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510245019

Publication Date:

October 29, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer.
The global market for Aflibercept Drug was estimated to be worth US$ 5617 million in 2023 and is forecast to a readjusted size of US$ 7305.9 million by 2030 with a CAGR of 3.8% during the forecast period 2024-2030
The Eylea market is primarily driven by the increasing prevalence of retinal diseases and the demand for effective treatments. Eylea (aflibercept) is a medication used to treat various eye conditions, including wet age-related macular degeneration (AMD) and diabetic macular edema. The growing aging population and the rise in chronic diseases like diabetes contribute to market growth. Moreover, advancements in ocular therapeutics and the demonstrated efficacy of Eylea in improving visual outcomes further propel adoption. However, challenges include managing the high cost of treatment and ensuring equitable access to care. Navigating the competitive landscape, optimizing treatment protocols, and addressing potential side effects are ongoing concerns. The market's success relies on continuous research to expand the indications for Eylea, collaborations between pharmaceutical manufacturers and ophthalmologists, and comprehensive patient education on the benefits and potential risks of treatment while addressing the evolving challenges associated with retinal disease management and treatment affordability.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Aflibercept Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Aflibercept Drug by region & country, by Type, and by Application.
The Aflibercept Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Aflibercept Drug.
麻豆原创 Segmentation
By Company
Regeneron
Bayer
Sanofi
Segment by Type:
Prefilled Syring Package
Vial Package
Segment by Application
Eye Disease
Cancer
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Aflibercept Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Aflibercept Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Aflibercept Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Aflibercept Drug Product Introduction
1.2 Global Aflibercept Drug 麻豆原创 Size Forecast
1.2.1 Global Aflibercept Drug Sales Value (2019-2030)
1.2.2 Global Aflibercept Drug Sales Volume (2019-2030)
1.2.3 Global Aflibercept Drug Sales Price (2019-2030)
1.3 Aflibercept Drug 麻豆原创 Trends & Drivers
1.3.1 Aflibercept Drug Industry Trends
1.3.2 Aflibercept Drug 麻豆原创 Drivers & Opportunity
1.3.3 Aflibercept Drug 麻豆原创 Challenges
1.3.4 Aflibercept Drug 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Aflibercept Drug Players Revenue Ranking (2023)
2.2 Global Aflibercept Drug Revenue by Company (2019-2024)
2.3 Global Aflibercept Drug Players Sales Volume Ranking (2023)
2.4 Global Aflibercept Drug Sales Volume by Company Players (2019-2024)
2.5 Global Aflibercept Drug Average Price by Company (2019-2024)
2.6 Key Manufacturers Aflibercept Drug Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Aflibercept Drug Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Aflibercept Drug
2.9 Aflibercept Drug 麻豆原创 Competitive Analysis
2.9.1 Aflibercept Drug 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Aflibercept Drug Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aflibercept Drug as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Prefilled Syring Package
3.1.2 Vial Package
3.2 Global Aflibercept Drug Sales Value by Type
3.2.1 Global Aflibercept Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Aflibercept Drug Sales Value, by Type (2019-2030)
3.2.3 Global Aflibercept Drug Sales Value, by Type (%) (2019-2030)
3.3 Global Aflibercept Drug Sales Volume by Type
3.3.1 Global Aflibercept Drug Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Aflibercept Drug Sales Volume, by Type (2019-2030)
3.3.3 Global Aflibercept Drug Sales Volume, by Type (%) (2019-2030)
3.4 Global Aflibercept Drug Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Eye Disease
4.1.2 Cancer
4.2 Global Aflibercept Drug Sales Value by Application
4.2.1 Global Aflibercept Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Aflibercept Drug Sales Value, by Application (2019-2030)
4.2.3 Global Aflibercept Drug Sales Value, by Application (%) (2019-2030)
4.3 Global Aflibercept Drug Sales Volume by Application
4.3.1 Global Aflibercept Drug Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Aflibercept Drug Sales Volume, by Application (2019-2030)
4.3.3 Global Aflibercept Drug Sales Volume, by Application (%) (2019-2030)
4.4 Global Aflibercept Drug Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Aflibercept Drug Sales Value by Region
5.1.1 Global Aflibercept Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Aflibercept Drug Sales Value by Region (2019-2024)
5.1.3 Global Aflibercept Drug Sales Value by Region (2025-2030)
5.1.4 Global Aflibercept Drug Sales Value by Region (%), (2019-2030)
5.2 Global Aflibercept Drug Sales Volume by Region
5.2.1 Global Aflibercept Drug Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Aflibercept Drug Sales Volume by Region (2019-2024)
5.2.3 Global Aflibercept Drug Sales Volume by Region (2025-2030)
5.2.4 Global Aflibercept Drug Sales Volume by Region (%), (2019-2030)
5.3 Global Aflibercept Drug Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Aflibercept Drug Sales Value, 2019-2030
5.4.2 North America Aflibercept Drug Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Aflibercept Drug Sales Value, 2019-2030
5.5.2 Europe Aflibercept Drug Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Aflibercept Drug Sales Value, 2019-2030
5.6.2 Asia Pacific Aflibercept Drug Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Aflibercept Drug Sales Value, 2019-2030
5.7.2 South America Aflibercept Drug Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Aflibercept Drug Sales Value, 2019-2030
5.8.2 Middle East & Africa Aflibercept Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Aflibercept Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Aflibercept Drug Sales Value
6.2.1 Key Countries/Regions Aflibercept Drug Sales Value, 2019-2030
6.2.2 Key Countries/Regions Aflibercept Drug Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Aflibercept Drug Sales Value, 2019-2030
6.3.2 United States Aflibercept Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Aflibercept Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Aflibercept Drug Sales Value, 2019-2030
6.4.2 Europe Aflibercept Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Aflibercept Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Aflibercept Drug Sales Value, 2019-2030
6.5.2 China Aflibercept Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Aflibercept Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Aflibercept Drug Sales Value, 2019-2030
6.6.2 Japan Aflibercept Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Aflibercept Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Aflibercept Drug Sales Value, 2019-2030
6.7.2 South Korea Aflibercept Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Aflibercept Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Aflibercept Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Aflibercept Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Aflibercept Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Aflibercept Drug Sales Value, 2019-2030
6.9.2 India Aflibercept Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Aflibercept Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Regeneron
7.1.1 Regeneron Company Information
7.1.2 Regeneron Introduction and Business Overview
7.1.3 Regeneron Aflibercept Drug Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Regeneron Aflibercept Drug Product Offerings
7.1.5 Regeneron Recent Development
7.2 Bayer
7.2.1 Bayer Company Information
7.2.2 Bayer Introduction and Business Overview
7.2.3 Bayer Aflibercept Drug Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Bayer Aflibercept Drug Product Offerings
7.2.5 Bayer Recent Development
7.3 Sanofi
7.3.1 Sanofi Company Information
7.3.2 Sanofi Introduction and Business Overview
7.3.3 Sanofi Aflibercept Drug Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Sanofi Aflibercept Drug Product Offerings
7.3.5 Sanofi Recent Development
8 Industry Chain Analysis
8.1 Aflibercept Drug Industrial Chain
8.2 Aflibercept Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Aflibercept Drug Sales Model
8.5.2 Sales Channel
8.5.3 Aflibercept Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Regeneron
Bayer
Sanofi

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.